Dr Herat and her team have secured funding to investigate if a new type of medication used to lower blood glucose levels in type 2 diabetes may also help reduce health complications in type 1 diabetes.  The $60,000 research grant will be used to study the effects of sotagliflozin – which inhibits two proteins, SGLT1 and SGLT2 – in type 1 diabetes.  The researchers believe the medication may provide superior protection to the heart and kidneys, with diabetes a leading cause of end-stage kidney and cardiovascular disease.